MaxCyte Investor Presentation Deck

A Leading Provider of Cell-Engineering Platform Technologies With 600+ platforms in place, our proprietary technology unlocks the significant potential of advanced therapeutics Leading the growing next-generation cell therapy market and capitalizing on rising demand for non-viral engineering approaches Ⓡ • Enables delivery of almost any molecule into almost any cell type • Leads the industry in performance (measured. by consistency, efficiency, viability, flexibility and scale) • Extensive product portfolio, supported by a robust intellectual property portfolio ● ~25% 5-Year CAGR of core revenue growth (2018-2022); pharmaceutical-like gross margins of ~89% (2018-2022) • 20+ years of cell engineering expertise; 30+ field sales and application scientists that support our customers* ● ● Significant number of collaborations with industry and academia FDA Master File and International Technical Files provide clear regulatory path, potentially reducing clinical risk/shortening clinical development Used to manufacture drug products for over 45 clinical trials to date 3 M MaxCyte Innovative business model focused on value creation and shared partnership success -P₂- • Allows MaxCyte to participate in the value created by our partners' programs ● • 23 SPL partnerships, which include approximately $2B in potential pre-commercial milestone payments with upside from commercial sales-based payments • Focused over the long-term on creating a diverse portfolio of patient treatments for indications developed by our strategic partners *As of December 31, 2022 © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation